Cannabis sativa as a clinically relevant nsLTP allergen in the Mediterranean region: a case series exemplifying different possible routes of sensitization.
A Bennici, D Grixti Soler, G Marcassa, G E Senna, S Gangemi, D Villalta, P L Minciullo
{"title":"Cannabis sativa as a clinically relevant nsLTP allergen in the Mediterranean region: a case series exemplifying different possible routes of sensitization.","authors":"A Bennici, D Grixti Soler, G Marcassa, G E Senna, S Gangemi, D Villalta, P L Minciullo","doi":"10.23822/EurAnnACI.1764-1489.374","DOIUrl":null,"url":null,"abstract":"<p><strong>Summary: </strong>Cannabis is the most widely used drug worldwide sought for recreational and medicinal purposes. Cannabis allergy was first described 50 years ago but has become more frequently reported over the past decade due to a larger industrial and domestic cultivation, and an evolving legal status. However, it remains an infrequent cause of allergy in the Mediterranean European countries. We describe three clinical cases with primary sensitization to cannabis characterized by anaphylactic reactions. We hypothesize that in all three case reports, sensitization to Can s 3 nsLTP played a crucial role in the development of anaphylaxis, either directly following ingestion of hemp-containing food, or even indirectly through primary sensitization via involuntary exposure or occupation exposure to cannabis sativa.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European annals of allergy and clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23822/EurAnnACI.1764-1489.374","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Summary: Cannabis is the most widely used drug worldwide sought for recreational and medicinal purposes. Cannabis allergy was first described 50 years ago but has become more frequently reported over the past decade due to a larger industrial and domestic cultivation, and an evolving legal status. However, it remains an infrequent cause of allergy in the Mediterranean European countries. We describe three clinical cases with primary sensitization to cannabis characterized by anaphylactic reactions. We hypothesize that in all three case reports, sensitization to Can s 3 nsLTP played a crucial role in the development of anaphylaxis, either directly following ingestion of hemp-containing food, or even indirectly through primary sensitization via involuntary exposure or occupation exposure to cannabis sativa.
摘要:大麻是全世界使用最广泛的药物,用于娱乐和医疗目的。大麻过敏在 50 年前首次被描述,但在过去十年中,由于工业和家庭种植规模的扩大以及法律地位的不断发展,大麻过敏的报告越来越频繁。然而,在地中海沿岸的欧洲国家,大麻仍然是一种不常见的过敏原。我们描述了三例以过敏反应为特征的大麻原发性过敏临床病例。我们假设,在所有这三个病例报告中,对 Can s 3 nsLTP 的致敏在过敏性休克的发生中起了至关重要的作用,这种致敏可能是在摄入含大麻的食物后直接发生的,也可能是通过非自愿接触或职业接触大麻而间接发生的原发性致敏。